SLNO
Soleno Therapeutics, Inc. · Healthcare · Biotechnology
At close
$40.51
+$1.44 (+3.68%) Close
Pre-market $42.94 +$2.43 (+6.00%) 12:07 AM ET
Prev close $39.07
Open $42.41
Day high $42.41
Day low $39.01
Volume 33,259
Avg vol 1,467,128
Mkt cap
$2.10B
P/E ratio
-21.66
FY Revenue
$98.68M
EPS
-1.87
Gross Margin
98.14%
Sector
Healthcare
AI report sections
SLNO
Soleno Therapeutics, Inc.
No AI report section text found yet for this symbol.
Volume vs average
Intraday (cumulative)
+25% (Above avg)
Vol/Avg: 1.25×
RSI
40.98 (Neutral)
Neutral (40–60)
MACD momentum
Intraday
+0.00 (Strong)
MACD: 0.09 Signal: 0.09
Short-Term
+0.17 (Strong)
MACD: -1.15 Signal: -1.32
Long-Term
+0.07 (Strong)
MACD: -2.44 Signal: -2.51
Intraday trend score 52.00

Latest news

SLNO 12 articles Positive: 2 Neutral: 2 Negative: 8
Negative GlobeNewswire Inc. • Hagens Berman
Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid Disappointing VYKAT XR Starts, Discontinuations; Shares Down 26% -- Hagens Berman

Soleno Therapeutics (SLNO) stock plunged 28% on November 5, 2025, after the company revealed disappointing launch metrics for VYKAT XR, including lower prescription starts and increased discontinuations due to adverse events. This contradicted the company's September 2025 statements that the launch had 'exceeded expectations.' Short seller Scorpion Capital had previously raised concerns about potential heart failure hospitalizations and questioned the validity of the company's trial data, citing irregularities in publications by a key investigator.

SLNO VYKAT XR Prader-Willi syndrome FDA approval adverse events clinical trial data integrity short seller report investor losses
Sentiment note

Stock declined 28% on disappointing launch data; company made contradictory statements about commercial prospects; short seller raised serious concerns about safety (heart failure hospitalizations), trial data integrity, and patent expiration; heavy dependence on single drug with no meaningful pipeline alternatives

Negative GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.
Bragar Eagel & Squire, P.C. Encourages Soleno, Avita, and Coty Investors to Contact the Firm Regarding Ongoing Investigations

Law firm Bragar Eagel & Squire is investigating potential securities violations at three companies: Soleno Therapeutics following a report questioning its product's safety and pricing, AVITA Medical due to significant claim payment backlogs affecting product utilization, and Coty following unexpected losses and disappointing guidance attributed to market challenges.

SLNO RCEL COTY securities investigation shareholder rights stock price decline financial results product safety
Sentiment note

Stock fell 7.41% following a critical report questioning the safety and pricing of its only product, Vykat XR, triggering a securities investigation.

Negative GlobeNewswire Inc. • Pomerantz Llp
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO

Pomerantz LLP is investigating potential securities fraud claims against Soleno Therapeutics following a short seller report questioning the safety and pricing of its product Vykat XR. The company disclosed an 8% discontinuation rate due to adverse effects and acknowledged disruption to its product launch. Soleno's stock fell 7.41% after the initial report and 26.59% following the earnings disclosure.

SLNO securities fraud class action lawsuit Vykat XR short seller report adverse effects stock price decline product discontinuation
Sentiment note

Company faces securities fraud investigation, significant stock price declines (7.41% and 26.59%), disclosed high discontinuation rates of its primary product due to adverse effects, and acknowledged disruption to product launch following negative short seller report.

Neutral Benzinga • Vandana Singh
Rhythm Pharma Strikes Chord As Early PWS Trial Results Show Promise

Rhythm Pharmaceuticals reported promising early Phase 2 trial results for setmelanotide in treating Prader-Willi syndrome, with potential therapeutic benefits in reducing BMI and extreme hunger. The company plans to advance to a Phase 3 trial and has initiated a new trial arm for a MC4R agonist.

RYTM SLNO Prader-Willi syndrome setmelanotide clinical trial genetic disorder obesity
Sentiment note

Mentioned for FDA approval of PWS treatment, but no direct performance details provided

Positive The Motley Fool • Jonathan Ponciano
Soleno Turns First Profit on $66 Million in Revenue — Is This Why One Investor Just Made an $87 Million Bet?

Soleno Therapeutics achieved its first profitable quarter with $66 million in revenue, attracting a significant $86.7 million investment from Connecticut-based fund Braidwell, which acquired 1.3 million shares in the biotechnology company.

SLNO KRYS biotechnology rare diseases profitability institutional investment
Sentiment note

First profitable quarter, doubled sequential revenue, successful commercial launch of VYKAT XR, significant institutional investment

Negative GlobeNewswire Inc. • Johnson Fistel, Pllp
Johnson Fistel Begins Investigation on Behalf of Soleno Therapeutics, Inc. (SLNO) Shareholders Who Have Incurred Losses

Johnson Fistel is investigating potential securities law violations by Soleno Therapeutics after the company disclosed challenges with its drug VYKAT™ XR launch, following a critical report by short seller Scorpion Capital that raised concerns about the product's safety and market potential.

SLNO securities investigation drug launch shareholder rights FDA approval stock volatility
Sentiment note

Stock price declined 40%, challenges emerged during product launch, potential securities law violations, and critical external report questioning drug safety and market sustainability

Positive GlobeNewswire Inc. • Brian Ritchie, Lifesci Advisors, Llc
Soleno Therapeutics to Participate in Upcoming November Conferences

Soleno Therapeutics will participate in multiple healthcare investor conferences in November 2025, presenting its rare disease therapeutic developments and potential investment opportunities.

SLNO investor conferences rare diseases healthcare therapeutics
Sentiment note

Company is actively engaging with investors, presenting at multiple conferences, and highlighting its novel therapeutic product for Prader-Willi syndrome, indicating growth and strategic communication efforts

Negative GlobeNewswire Inc. • Rosen Law Firm
SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Rosen Law Firm is investigating potential securities claims for Soleno Therapeutics shareholders following a Scorpion Capital short report that raised concerns about their Prader-Willi syndrome treatment, VYKAT XR.

SLNO securities claim short report investor losses Prader-Willi syndrome
Sentiment note

Stock fell 7.4% and 4.9% on consecutive trading days after a short report suggested potential safety issues and risk of market withdrawal for their drug VYKAT XR

Neutral GlobeNewswire Inc. • Cassava Sciences, Inc.
Cassava Sciences Appoints Dawn C. Bir to the Board of Directors

Biotechnology company Cassava Sciences announced the appointment of Dawn C. Bir to its Board of Directors, bringing extensive biopharmaceutical executive experience to support the company's clinical development of simufilam for TSC-related epilepsy.

SAVA GERN SLNO BIIB biotechnology board appointment simufilam TSC-related epilepsy
Sentiment note

Mentioned as a current board position for Dawn Bir

Negative GlobeNewswire Inc. • Rosen Law Firm
SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Rosen Law Firm is investigating potential securities claims for Soleno Therapeutics shareholders after a Scorpion Capital short report raised concerns about their Prader-Willi syndrome treatment, causing stock price decline.

SLNO securities claim short report stock decline Prader-Willi syndrome
Sentiment note

Stock fell 7.4% and 4.9% on consecutive trading days after a short report highlighted potential safety issues and risks of market withdrawal for their drug VYKAT XR

Negative GlobeNewswire Inc. • Rosen Law Firm
SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Rosen Law Firm is investigating potential securities claims for Soleno Therapeutics shareholders following a Scorpion Capital short report that raised concerns about their Prader-Willi syndrome treatment, VYKAT XR.

SLNO securities claim short report investor losses Prader-Willi syndrome
Sentiment note

Stock price dropped 7.4% and 4.9% on consecutive trading days after a short report highlighted potential safety issues and risks of market withdrawal for their drug VYKAT XR

Negative GlobeNewswire Inc. • Rosen Law Firm
SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Rosen Law Firm is investigating potential securities claims for Soleno Therapeutics shareholders following a Scorpion Capital short report that raised concerns about their Prader-Willi syndrome treatment, VYKAT XR.

SLNO securities claim short report investor losses Prader-Willi syndrome
Sentiment note

Stock fell 7.4% and 4.9% on consecutive trading days after a short report suggested potential safety issues and risk of market withdrawal for their drug VYKAT XR

News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal